human cd163 duoset elisa  (Bio-Techne corporation)

Journal: Viruses

Article Title: Monocyte Dynamics in Chikungunya Fever: Sustained Activation and Vascular-Coagulation Pathway Involvement

doi: 10.3390/v17091224

Figure Lengend Snippet: Circulating plasma levels of soluble CD163 (sCD163) and monocyte subsets during the acute (n = 53), post-acute (n = 4), and chronic (n = 8) phases of CF. ( A ) Plasma levels of soluble CD163 (sCD163) in CF patients and healthy donors (HD). ( B ) Paired comparison of sCD163 plasma levels. Time Point 1 (T1) represents the first sample collected during the acute or post-acute phase, and Time Point 2 (T2) represents the second sample collected during the chronic phase. ( C ) Representative dot plot from a CHIKV-infected patient in the acute phase showing monocyte subsets. ( D ) Representative histograms of CD163, HLA-DR, TLR4, and TLR7 expression on classical, intermediate, and non-classical monocytes. ( E ) Percentages of circulating classical (CD14++CD16−), intermediate (CD14+CD16+), and non-classical (CD14+CD16++) monocytes analyzed in CF patients during the acute (n = 20), post-acute (n = 3), and chronic (n = 6) phases, and in healthy donors (HD, n = 10). Data are presented as medians with interquartile ranges (IQR). Statistical analysis: one-way ANOVA followed by Kruskal–Wallis and Dunn’s multiple comparisons test; Wilcoxon signed-rank test for paired comparisons. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.

Article Snippet: A commercial Human CD163 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) was used for the same.

Techniques: Clinical Proteomics, Comparison, Infection, Expressing

Journal: Viruses

Article Title: Monocyte Dynamics in Chikungunya Fever: Sustained Activation and Vascular-Coagulation Pathway Involvement

doi: 10.3390/v17091224

Figure Lengend Snippet: Expression of activation markers on monocyte subsets. ( A ) Comparison of CD163 expression on monocyte subsets from CF patients during acute (n = 20), post-acute (n = 3), and chronic phases (n = 6) in HD (n = 10). ( B ) Comparison of HLA-DR expression on monocyte subsets from CF patients during acute (n = 20), post-acute (n = 3), and chronic phases (n = 6) and in HD (n = 10). ( C ) Comparison of TLR4 expression on monocyte subsets from patients in the acute (n = 12), post-acute (n = 3) and chronic (n = 6) phases, and in HD (n = 10). ( D ) Comparison of TLR7 expression on monocyte subsets from patients in the acute (n = 20). Post-acute (n = 3) and chronic phases (n = 6) phases, and in HD (n = 10). Mean fluorescence intensity (MFI) of labeled cells was determined by flow cytometry. Data are presented as medians with interquartile ranges (IQRs). Statistical analysis: one-way ANOVA followed by Kruskal–Wallis test and Dunn’s multiple comparisons test and using the Mann–Whitney test. * p < 0.05; ** p < 0.01.

Article Snippet: A commercial Human CD163 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA) was used for the same.

Techniques: Expressing, Activation Assay, Comparison, Fluorescence, Labeling, Flow Cytometry, MANN-WHITNEY

Journal: Liver International

Article Title: Macrophage activation markers are associated with infection and mortality in patients with acute liver failure

doi: 10.1111/liv.15928

Figure Lengend Snippet: Macrophage activation markers in the serum of patients with acute liver failure (ALF) measured by enzyme‐linked immunosorbent assay (ELISA). Six molecules were measured from the cohort of patients with ALF in the acute liver failure study group early (Days 1–3 following admission to hospital) and late (Day 3+) in the course of disease and healthy controls (HC) from volunteers at King's College Hospital. (A, E) Secretory leukocyte peptidase inhibitor (SLPI) and soluble macrophage mannose receptor (sMR) concentrations are higher in both early and late groups compared to HC. (B, F) soluble cluster of differentiation 163 (sCD163) and soluble programmed death ligand 1 (sPD‐L1) concentrations are higher ALF (both groups) compared to HC and higher in early compared to late groups. (C) Soluble Mer tyrosine kinase (sMerTK) concentrations are higher in the early group compared to HC and to the late group. (D) Osteopontin (OPN) concentrations are higher in the early group compared to the late one. * p < .05, ** p < .01, *** p < .001, **** p < .0001.

Article Snippet: The following assays were used according to the manufacturers' instructions: Human SLPI Quantikine ELISA (R&D Systems; DP100), Human CD163 Duoset ELISA (R&D Systems; DY1607‐05), Human OPN ELISA (Bio‐Techne; DY1433), Human MerTK kit (Bio‐Techne; DYC891‐5), Human MMR (CD206) ELISA (Insight Biotechnology; ELH‐MMR) and Human PD‐L1 ELISA (ThermoFisher; BMS2212 and BMS2212TEN).

Techniques: Activation Assay, Enzyme-linked Immunosorbent Assay